= Abstract = Purpose : Taurine (2-aminoethanesulfonic acid) is a simple sulfur-containing amino acid. It is abundantly present in tissues such as brain, retina, heart, and skeletal muscles. Current studies have demonstrated the neuroprotective effects of taurine, but limited data are available for such effects during neonatal period. The aim of this study was to determine whether taurine could reduce hypoxic-ischemic (HI) cerebral injury via anti-apoptosis mechanism. Methods : Embryonic cortical neurons isolated from Sprague-Dawley (SD) rats at 18 days gestation were cultured in vitro. The cells were divided into hypoxia group, taurine-treated group before hypoxic insult, and taurine-treated group after HI insult. In the in vivo model, left carotid artery ligation was performed in 7-day-old SD rat pups. The pups were exposed to hypoxia, administered an injection of 30 mg/kg of taurine, and killed at 1 day, 3 days, 1 week, 2 weeks, and 4 weeks after the hypoxic insult. We compared the expressions of Bcl-2, Bax, and caspase-3 among the 3 groups by using realtime polymerase chain reaction (PCR) and western blotting. Results : The cells in the taurine-treated group before hypoxic insult, although similar in appearance to those in the normoxia group, were lesser in number. In the taurine-treated group, Bcl-2 expression increased, whereas Bax and caspase-3 expressions reduced. Conclusion : Taurine exerts neuroprotective effects onperinatal HI brain injury due to its anti-apoptotic effect. The neuroprotective effect was maximal at 1-2 weeks after the hypoxic injury. (Korean J Pediatr 2009;52:1337-1347 
development 1) . Glutamate is the main excitatory transmitter in the brain stem. This sulfonic acid is thought to have a special role in the developing brain tissue. In other words taurine has been thought to be essential for the development and survival of neural cells. It is inhibitory and functions as a neuromodulator in the brain. Its function as a neurotransmitter implies the existence of specific taurine receptors and the neuromodulatory role, an interference with functions of other transmitter systems 2) . Taurine may also have potential for neuroprotection in cerebral ischemia 3) . It release is markedly enhanced under ischemic conditions. It protects neural cells from excitotoxicity induced by excitatory amino acids in the hippocampus 4) and cerebellum 5) . It has the ability to forestall harmful metabolic events evoked by ischemia and hypoxia 6) and to attenuate Ca 2+ influx during ischemia 7) . Pretreatment with taurine (0.5, 1 or 2 mmol/L) could aid in the recovery of synaptic function in rat hippocampus following a standardized hypoxic insult. Using in vivo rat brain ischemic models, several studies have documented the neuroprotective effect of taurine (200-300 mg/kg) under cell-damaging conditions 8) .
The association of taurine with apoptosis, which is regarded as the major mechanism for the resolution of brain injury, has been examined in various cell types. Taurine inhibited arsenite-induced apoptosis of human PMN cells 9) and endothelial cell apoptosis 10) . Release of taurine from the cell through a CD 95 receptor and caspase dependent mechanism leads the triggering of apoptotic DNA fragmentation and cell shrinkage 11) .
Numerous studies have shown that different experimental models of hypoxia and/or ischemia (e.g., anoxia, hypoxia, combined hypoxia, and ischemia) in neonatal animals can produce relatively predictable brain injuries [12] [13] [14] [15] [16] and that these brain injuries appear similar to those seen clinically in humans [17] [18] [19] [20] [21] . A commonly used neonatal rat model to in- This procedure leads to cerebral damage restricted to the hemisphere ipsilateral to the occluded artery 16) . The neonatal rat HI model has been well characterized and extensively used to assess synthetic neuroprotective agents 22) .
Neuroprotective drugs aim to salvage ischemic tissues, limit infarct size, prolong the window for reperfusion therapy or minimize post-ischemic reperfusion injury or inflammation. Current studies have demonstrated the neuroprotective effect of taurine in adult rat model, but limited data are available for those during the neonatal periods.
Due to the dramatic differences in the physiology of perinatal and adult brains, the efficient treatment of HI encephalopathy in the perinatal period is likely different to those in adults.
The aim of this study was to determine whether taurine could reduce cerebral injury due to hypoxic-ischemic in the developing brain through anti-apoptosis using in vitro and in vivo models.
Materials and Methods

Embryonic cortical neuronal cell cultures
The rat embryonic cortical neuronal cell culture procedure was based on the Brewer method 23) . Pregnant Spra- . They were cultured in 5% CO2 incubator for fortyeight hours, after which cytosine arabinoside (3 μmol/mL) was added and left for another 48 hours to kill glial cells.
The cultured cells were divided into two groups and were designated as the normoxia group and the hypoxia group.
The normoxia group was cultured in 5% CO2 incubators and the hypoxia group and the taurine-treated group before a hypoxic insult were placed in 1% O2 incubators (94% N2, 5% CO2) for several hours. After verifying the desired amount of cellular injury in the hypoxia group, the taurinetreated group after a hypoxic insult was further divided.
This produced four final groups; namely-normoxia, hypoxia, taurine-treated group before a hypoxic insult and taurine-treated group after a hypoxic insult.
The MTT assay was used for estimation of cell viability and growth as originally described by Mosmann 24) . MTT 
Animal protocols
This study was performed in accordance with the approved animal use guidelines of the Catholic University of Daegu. The protocol for the newborn animal model of HI brain injury was based on a modification of the Levine preparation described by Rice et al 16) . Left carotid artery ligation was done in 7-day-old SD rat pups under ether anes- 
Protein isolation and western-blotting
Statistical analysis
Data were analyzed using the SPSS version 12 statistical analysis package. Examined data were assessed using the T-test, GLM (general lineal model) and ANOVA. In each test, the data are expressed as the mean SD and a P value =equal to 0.05 was accepted as statistically significant.
Results
Images of cortical neuronal cultured cells from rat embryos with taurine treatment
The growth of embryonic cortical neuronal cells was observed with a phase contrast microscope (×400). Cells in the normoxia group (Fig. 1A) appeared normal, while cells in the hypoxia group (Fig. 1B) showed cellular swelling with indistinct nuclear shapes. Cells in the taurine-treated group before a hypoxic insult (Fig. 1C) had a similar appearance to those in the normoxia group, while the cells in the taurine-treated group after a hypoxic insult (Fig. 1D) were less numerous than in the taurine-treated group before a hypoxic insult.
Cell viability of cultured cortical neuronal cells, determined by the MTT assay
To determine the protective effects of taurine in the cultured cortical neuronal cells after a hypoxic insult, the relative cell viability of taurine was developed. In the hypoxia group, cells were reduced compared to the normoxia group. However, cell viability of the taurine-treated group before a hypoxic insult was similar to one in the normoxia group, while cell viability of the taurine-treated group after a hypoxic insult did not return to level of the normoxia group or the taurine-treated group before a hypoxic insult (Fig. 2) .
3. The expression of Bcl-2, Bax and caspase-3 mRNA by real-time PCR in cultured cortical neuronal cells
The expression of Bcl-2 mRNA, which are indicators of the level of anti-apoptosis, was more reduced in the hy- poxia group than in the normoxia group, and was increased in the taurine-treated group before a hypoxic insult compared to the hypoxia group. In contrast, the expression of Bax & caspase-3 mRNA and the ratio of Bax/Bcl-2 expression, which are indicators of the level of pro-apoptosis, were more increased in the hypoxia group than in the normoxia group, and were decreased in the taurine-treated group before a hypoxic insult compared to the hypoxia group. The expressions of Bcl-2, Bax and caspase-3 mRNA in the taurine-treated group after a hypoxic insult was similar to those in the hypoxia group or did not return to level of the normoxia group or the taurine-treated group before a hypoxic insult (Fig. 3) .
The expression of Bcl-2, Bax and caspase-3 by western blotting in cultured cortical neuronal cells
The expression of Bcl-2 was more reduced in the hypoxia group than in the normoxia group and was slightly increased in the taurine-treated group before and after a hypoxic insult compared to the hypoxia group. In contrast, the expression of Bax and the ratio of Bax/Bcl-2 expression were more increased in the hypoxia group than in the normoxia group and were decreased in the taurine-treated group before and after a hypoxic insult compared to the hypoxia group. However, the expression of caspase-3 were more increased in the hypoxia group than in the normoxia group and were decreased in the taurine-treated group before and after a hypoxic insult compared to the hypoxia group. The expressions of caspase-3 in the taurine-treated group after a hypoxic insult was similar to those in the hypoxia group (Fig. 4) .
5. The expression of Bcl-2, Bax and caspase-3 mRNA at 1 day, 3 days, 1 week, 2 weeks, and 4 weeks after a hypoxic insult by real-time PCR in neonatal HI brain injury
At 1 day, 3 days, 1 week, 2 weeks, and 4 weeks after a hypoxic insult, the expression of Bcl-2 mRNA was more reduced in the hypoxia group than in the normoxia group, and was increased in the taurine-treated group before a hypoxic insult compared to the hypoxia group. In contrast, the expression of Bax and caspase-3 mRNA were more increased in the hypoxia group than in the normoxia group, and were decreased in the taurine-treated group before a hypoxic insult compared to the hypoxia group. The expressions of Bcl-2 and Bax in the taurine-treated group after a hypoxic insult were similar to those in the hypoxia group and the expressions of caspase-3 in the taurine-treated group after a hypoxic insult was more decreased in proportion of the duration after a hypoxic insult (Fig. 5) .
6. The expression of Bcl-2, Bax and caspase-3 at 1 day, 3 days, 1 week, 2 weeks, and 4 weeks after a hypoxic insult by western blotting in neonatal HI brain injury
At 1 week and 2 weeks after a hypoxic insult, the expression of Bcl-2 was more reduced in the hypoxia group than in the normoxia group, and was increased in the taurine-treated group before a hypoxic insult as compared to the hypoxia group. In contrast, the expression of Bax and caspase-3 were more increased in the hypoxia group than in the normoxia group, and decreased in the taurine-treated group before a hypoxic insult compared to the hypoxia group, However, at 1 day, 3 days and 4 weeks after a hy- poxic insult the expressions of Bcl-2, Bax and caspase-3 were different from the data of real-time PCR that we expected. Probably protein expression may be delayed and disappear early compare to mRNA expression (Fig. 6) .
Discussion
Taurine has a number of physiological functions. It is a component of bile acids, which are used to help absorb fats and fat-soluble vitamins. It also helps regulate the heart beat, maintain cell membrane stability and prevent brain cell over-activity 25) . It is a major constituent of bile and can be found in lower amounts in the tissues of many animals including humans 26) . Taurine originated from the Latin word taurus, which means bull or ox, as it was first isolated from ox bile in 1827 by Austrian scientists Friedrich Tiedemann and Leopold Gmelin 27) . It is often considered an amino acid in scientific literatures 27) . It is a vital nutrient for cats, and probably also for primates, since it is essential for the development and survival of neural cell 28) . HI encephalopathy triggers an immediate neuronal and glial injury leading to necrosis secondary to cellular edema and lysis. Early congestion, fluid leak from increased capillary permeability and endothelial cell swelling may then lead to coagulation necrosis and cell death. The injury also triggers apoptosis resulting in delayed cellular death 29) .
Taurine is known to protect neural cells from the excitotoxicity induced by excitatory amino acids 30) . In the central nervous system, it has been implicated in inhibitory neuro- . Taurine protects cerebellar granular cells exposed to kainate without affecting the production of reactive oxygen species in these cells 32) .
The extracellular concentrations of taurine together with other amino acids have been measured by microdialysis in several in vivo animal models of ischemic injury. The levels were increased in the rat striatum 33) and rabbit cerebral cortex 34) after transient focal ischemia, in the rat cerebral cortex in the four-vessel occlusion model, in the rabbit spinal cord after aortic occlusion 35) and in the hippocampus after forebrain ischemia both in normal 36) and spontaneously hypertensive rats 37) . In this latter experimental paradigm, the ischemia-induced release of taurine was smaller in aged rats than in adults, indicating the age-related vulnerability of hippocampal neurons to ischemia 37) . In a global model of brain ischemia, taurine accumulated in the rat auditory cortex and cerebrospinal fluid 38) .
In a hypoxic rat model, taurine prevented hypoxia-induced lactate accumulation and lipid peroxidation in the brain, liver, and heart tissues 39) . Besides its reported antioxidant effect, taurine has a GABA-A agonist activity. High concentrations of taurine is present in mammalian central nervous system and it is believed to be involved in osmoregulation and cell volume adjustments 28) . Growing evidences suggest that taurine may function as a potent inhibitory neurotransmitter or a modulator that regulates neuronal activity in many cerebral areas.
We studied the neuroprotective effect of taurine using . Immature cortical neurons are highly susceptible to apoptosis, and apoptosis has a prolonged role in neurodegeneration after HI in the newborn rat. In addition, HI damage generally evolves more rapidly in the immature brain than its adult counterpart 16) .
The prevention of apoptosis may potentially expand the therapeutic window for the treatment of perinatal HI brain injury.
Using the HI neonatal rat model, we compared the results of assays for some apoptotic markers from the control group, the hypoxia group, and the taurine-treated groups (pre-treatment, post-treatment). The results showed that in the taurine-treated group before a hypoxic insult, the Bcl-2, an anti-apoptotic protein, was relatively increased while Bax and caspase-3, both pro-apoptotic proteins, were relatively decreased. Bax/Bcl-2 ratio also decreased.
These results suggest that the neuroprotective effect of taurine is associated with the apoptosis cascade.
The expression of Bcl-2 mRNA by real-time PCR in neonatal HI brain injury (in vivo) was more reduced in the hypoxia group than in the normoxia group, and was increased in the taurine-treated group before a hypoxic insult at all periods (1 day, 3 days, 1 week, 2 weeks, 4
weeks) compared to the hypoxia group. In contrast, the expression of Bax and caspase-3 mRNA were more increased in the hypoxia group than in the normoxia group, and were decreased in the taurine-treated group before a hypoxic insult at all periods compared to the hypoxia group.
The expression of Bcl-2 by western blot in neonatal HI brain injury (in vivo) was more reduced in the hypoxia group than in the normoxia group, and was increased in the taurine-treated group before a hypoxic insult at 1 week and 2 weeks compared to the hypoxia group. In contrast, the expressions of Bax and caspase-3 were more increased in the hypoxia group than in the normoxia group, and were decreased in the taurine-treated group before a hypoxic insult at 1 and 2 weeks compared to the hypoxia group.
However, at 1 day, 3 days and 4 weeks after a hypoxic insult the expressions of Bcl-2, Bax and caspase-3 were different from the data of real-time PCR that we expected. 
